Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Opioid Dependence
Interventions: CI-581aa, Naltrexone titration and XR-NTX initiation; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Prostate Cancer
Interventions: Naltrexone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Opiate Dependence
Interventions: Mobile Access; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Sedation
Interventions: Midazolam, Fentanyl/Morphine, Dexmedetomidine; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 28 Weeks to 44 Weeks
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 17
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 14 more

Conditions: Cervical Cancer, Uterine Endometrial Cancer, Ovarian Cancer
Interventions: Laparotomy, intravenous narcotics, standard anesthesia, regional anesthesia, Non-steroidal anti-inflammatory drugs; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 19 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Opiate Withdrawal Syndrome
Interventions: Percutaneous Electrical Nerve Field Stimulation; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Tonsillitis, Pain
Interventions: Codeine with acetaminophen, Tramadol suspension; Drug
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 4 Years to 15 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pain, Postoperative
Interventions: Methadone, Morphine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-operative Pain
Interventions: Bupivacaine, Botulinum Toxins, Analgesics; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opiate Addiction
Interventions: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Use and Disposal
Interventions: Pamphlet education, Pamphlet education + texts; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 563 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opiate Dependence
Interventions: Remote Observed Dosing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Leandro, California • Portland, Maine + 2 more

Conditions: Cocaine-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lumbar Spinal Stenosis
Interventions: opana then darvocet then placebo, opana then placebo then darvocet, placebo then opana then darvocet, Placebo then darvocet then opana, Darvocet then opana then placebo, Darvocet then placebo then opana; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Opiate Addiction, Pregnancy
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Social Acceptance
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Tristen Inagaki; Other
Eligibility: 18 Years to 35 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opiate-Related Disorders, Opiate Use Disorder, Opioid
Interventions: MedSMA℞T Mobile; Behavioral
Lead sponsor: Olufunmilola Abraham; Other
Eligibility: 12 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 3
States / cities: Rockford, Illinois • Madison, Wisconsin

Conditions: Alcoholism
Interventions: naltrexone (Revia), Compliance Enhancement Tech., Cognitive Behavior Therapy; Drug · Behavioral
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Dependence
Interventions: Depot naltrexone, Oral Naltrexone; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: darunavir/ritonavir, lopinavir/ritonavir, Midazolam, Dextromethorphan, Flurbiprofen, GSK2248761; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neonatal Abstinence Syndrome
Interventions: Morphine, Clonidine; Drug
Lead sponsor: Henrietta Bada; Other
Eligibility: 1 Day to 7 Days
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opiate Addiction
Interventions: Lofexidine, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Cerritos, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more

Conditions: Chronic Low Back Pain
Interventions: ABT-712, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 21 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 32
States / cities: Tempe, Arizona • Tucson, Arizona • Anaheim, California + 26 more

Search by objective public record fields.

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance

Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age

Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study

Neurostimulation for Opiate Withdrawal in the PICU

A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy

Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia

A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

Impacting the Disposal of Unused Opioid

Remote Observed Dosing to Increase Suboxone Compliance

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1

Lumbar Stenosis Outcomes Research II

Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics

An fMRI Study of Opioid-related Changes in Neural Activity

MedSMA℞T Mobile ED

Naltrexone Treatment of Alcohol Dependence

Pilot Study of Depot NTX in Homeless Veterans

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

NAS Treatment - Opiate Versus Non-Opiate

Lofexidine for Inpatient Opiate Detox

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)